( HAE:TSX MONTREAL June 14 2007 /PRN...)Haemacure Announces Preliminary Findings of its Plasma Discard,Analysis,Health

HAE:TSX

MONTREAL, June 14, 2007 /PRNewswire-FirstCall/ Haemacure Corporation , a Montreal-based specialty biotherapeutics company, today announced the preliminary findings of the content analysis of one of its plasma discards.

Preliminary findings confirm the presence of a number of proteins and enzymes with applications in significant worldwide markets, including albumin, plasminogen, immunoglobulin and A1PI.

These findings take on a strategic significance for Haemacure as revenues eventually generated from the commercial exploitation of these proteins and enzymes will constitute a direct contribution to the bottom line. This is because the cost of the plasma will be fully borne by Haemacure's fibrin sealant and hemostatic agent once these products will be commercialized.

"We are very excited with the positive outcome of the content analysis of one of our plasma discards," said Joseph Galli, Chairman and Chief Executive Officer of Haemacure. "This is the first tangible result of our new biotherapeutics orientation that we announced at our recent meeting of shareholders. The identification of these proteins and enzymes indicates that our patented plasma protein extraction technology yields significant potential benefits superior to the traditional extraction technology. With these results in hand, and further to interest expressed by third parties in our plasma discard, we will drive towards implementing our business development strategy that encompasses partnerships with pharmaceutical and biotechnology companies." concluded Mr. Galli.

Haemacure plans on harvesting albumin from this discard and using it in the production of its fibrin sealant, representing annual cost savings estimated at more than US$500,000 at full production plant capacity. Some albumin extracted could also be available for commercialization.

According to the Marketing Research Bureau, the world pla
'"/>